Focus Stocks

Hewlett Packard (HPQ)

Hewlett Packard (HPQ)


Dell (DELL)

Dell (DELL)


Facebook (FB)

Facebook (FB)


Apple (AAPL)

Apple (AAPL)


Goldman Sachs (GS)

Goldman Sachs (GS)


Featured Stories

Fred's First Quarter 2012 EPS Increase 17%

Fred's First Quarter 2012 EPS Increase 17%


Newell Rubbermaid to Reaffirm Fiscal Year 2012 Outlook

Newell Rubbermaid to Reaffirm Fiscal Year 2012 Outlook


Best ETFs For Facebook Exposure

Best ETFs For Facebook Exposure


McDonald's Announces Quarterly Cash Dividend

McDonald's Announces Quarterly Cash Dividend


Is KB HOME Closing in to Resistance?

Is KB HOME Closing in to Resistance?


GSK Upbeat on Solid Results - Interviews with CEO and CFO


LONDON, February 7, 2012 /PRNewswire/ --

In an online video interview with MerchantCantos, GlaxoSmithKline CEO Sir Andrew Witty talks about the pharmaceutical group's special dividend, solid results and why the company is so well positioned to continue to deliver.

Sir Andrew said "adversity isn't all downside for everybody" and that the market offered opportunities for companies who had strengthened and had changed their exposure to places of growth.

"This is a time where we should feel optimistic. And certainly at GSK we do feel optimistic.  We feel like are moving into a new era for the company and we now need to focus on absolute disciplined execution to make sure that we take advantage of all of the opportunities that we've worked so hard to try and create for ourselves."

CFO Simon Dingemans admitted there had been some margin pressure in Q4 but that he expected margins to improve gradually. "We expect only a very gradual increase in operating margin, and by that I mean a few tens of basis points and more in 2013 and further thereafter."

The interviews and transcripts are available now on http://www.cantos.com/company/GlaxoSmithKline.

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email This e-mail address is being protected from spambots. You need JavaScript enabled to view it. or phone +44-207-936-1352.

SOURCE GlaxoSmithKline



JIM CRAMER wants to work for YOU. JIM does the research -- YOU get email alerts each time he trades. JIM provides access to his actual portfolio -- YOU can use it to guide your portfolio strategy. Try Jim's Action Alerts PLUS for FREE!

TradersHuddle Search

Sponsored By:

Stock Search:


Site Search:

Loading

Copyright © 2011 TradersHuddle.com. All Rights Reserved.